- Previous Close
14.42 - Open
14.46 - Bid 13.56 x 600
- Ask 13.62 x 1200
- Day's Range
13.18 - 14.70 - 52 Week Range
3.53 - 23.86 - Volume
7,537,471 - Avg. Volume
6,800,101 - Market Cap (intraday)
2.179B - Beta (5Y Monthly) 2.03
- PE Ratio (TTM)
-- - EPS (TTM)
-2.62 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.00
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
www.novavax.comRecent News: NVAX
View MorePerformance Overview: NVAX
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVAX
View MoreValuation Measures
Market Cap
2.18B
Enterprise Value
1.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.14
Price/Book (mrq)
--
Enterprise Value/Revenue
2.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.80%
Return on Assets (ttm)
-10.21%
Return on Equity (ttm)
--
Revenue (ttm)
987.67M
Net Income Avi to Common (ttm)
-294.33M
Diluted EPS (ttm)
-2.62
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-97.84M
Research Analysis: NVAX
View MoreCompany Insights: NVAX
NVAX does not have Company Insights